外用ROR反向激动剂抑制小鼠特应性皮炎与急性刺激性皮炎炎症
研究评估合成RORα/γ反向激动剂SR1001在小鼠特应性皮炎和急性刺激性皮炎模型中的抗炎潜力。外用SR1001可减轻MC903诱导的特应性皮炎样皮损的表皮和真皮特征,抑制2型细胞因子及炎症介质产生,阻断TSLP表达并逆转角质形成细胞分化障碍,对TPA诱导的急性皮炎也有效。提示RORα/γ是皮肤炎症的重要治疗靶点,外用抑制性配体可能用于炎症性皮肤病。
要点
- 外用SR1001可减轻MC903诱导的小鼠特应性皮炎样皮损。
- SR1001抑制皮损中2型细胞因子和炎症介质产生。
- SR1001阻断表皮TSLP表达并逆转角质形成细胞分化障碍。
核心结论
- RORα/γ是皮肤炎症的重要治疗靶点,外用抑制性配体可能用于治疗炎症性皮肤病。
研究设计与样本
- 在小鼠特应性皮炎和急性刺激性皮炎模型中研究SR1001(合成RORα/γ反向激动剂)的抗炎作用。
主要发现
- 外用SR1001减轻MC903诱导的特应性皮炎样病的表皮和真皮特征。
- SR1001抑制皮损中2型细胞因子和其他炎症介质的产生。
- SR1001阻断MC903诱导的表皮TSLP表达并逆转受损的角质形成细胞分化。
- SR1001减轻12-O-十四烷酰佛波醇-13-乙酸酯触发的急性皮炎。
临床怎么用
- 提示外用RORα/γ反向激动剂可能作为炎症性皮肤病的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The retinoic acid receptor-related orphan receptors RORα and RORγ are critical for the functions of specific subsets of T cells and innate lymphoid cells, which are key drivers of inflammatory disease in barrier tissues. Here, we investigate the anti-inflammatory potential of SR1001, a synthetic RORα/γ inverse agonist, in mouse models of atopic dermatitis and acute irritant dermatitis. Topical treatment with SR1001 reduces epidermal and dermal features of MC903-induced atopic dermatitis-like disease and suppresses the production of type 2 cytokines and other inflammatory mediators in lesional skin. In the epidermis, SR1001 treatment blocks MC903-induced expression of TSLP and reverses impaired keratinocyte differentiation. SR1001 is also effective in alleviating acute dermatitis triggered by 12-O-tetradecanoylphorbol-13-acetate. Overall, our results suggest that RORα/γ are important therapeutic targets for cutaneous inflammation and suggest topical usage of inhibitory ligands as an approach to treating skin diseases of inflammatory etiology.
引用
- Dai J, Choo MK, Park JM, et al. Topical ROR Inverse Agonists Suppress Inflammation in Mouse Models of Atopic Dermatitis and Acute Irritant Dermatitis. J Invest Dermatol. 2017. PMID: 28774591. doi:10.1016/j.jid.2017.07.819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。